Okamura K, Sato K, Ikenoue H, Yoshinari M, Nakagawa M, Kuroda T, Fujishima M
Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
J Clin Endocrinol Metab. 1988 Oct;67(4):720-6. doi: 10.1210/jcem-67-4-720.
The clinical significance of the thyroidal radioactive iodine uptake (RAIU) test was reevaluated in patients with various thyroid disorders. Compared with 262 normal subjects or 194 patients with euthyroid diffuse goiter with normal serum TSH levels, RAIU values were significantly higher in 100 patients with latent primary hypothyroidism (serum TSH, 5-40 mU/L). In 126 patients with overt primary hypothyroidism (serum TSH, greater than 40 mU/L), RAIU values were either extremely high (49 patients with reversible hypothyroidism and 10 patients with postpartum hypothyroidism) or low (67 patients with irreversible hypothyroidism). The increase in RAIU values in latent, or reversible overt hypothyroidism was TSH dependent, and there was a good correlation between RAIU values and serum TSH levels (r = 0.6203; P less than 0.001). In overt primary hypothyroidism, spontaneous recovery of thyroid function during iodide restriction alone occurred in 52 of 53 patients with RAIU values above 35%, in only 7 of 23 patients with RAIU values between 10-35%, and in none of 50 patients with RAIU below 10%. Thus, recovery was predicted by high RAIU values (P less than 0.001; prediction rate, 91.4%). Goiter was found in about 80% of the patients with reversible hypothyroidism, compared with only 34% of the patients with irreversible hypothyroidism. Recovery of thyroid function during iodide restriction also occurred in 71% of the patients with latent hypothyroidism. However, RAIU measurements did not predict the prognosis of patients with latent hypothyroidism. We conclude that iodine-induced reversible hypothyroidism is common in our patient population, and RAIU measurements may be helpful in determining the prognosis of patients with overt primary hypothyroidism.
对患有各种甲状腺疾病的患者重新评估了甲状腺放射性碘摄取(RAIU)试验的临床意义。与262名正常受试者或194名血清TSH水平正常的甲状腺功能正常的弥漫性甲状腺肿患者相比,100名潜在原发性甲状腺功能减退患者(血清TSH,5 - 40 mU/L)的RAIU值显著更高。在126名显性原发性甲状腺功能减退患者(血清TSH大于40 mU/L)中,RAIU值要么极高(49名可逆性甲状腺功能减退患者和10名产后甲状腺功能减退患者)要么很低(67名不可逆性甲状腺功能减退患者)。潜在或可逆性显性甲状腺功能减退中RAIU值的升高依赖于TSH,且RAIU值与血清TSH水平之间存在良好的相关性(r = 0.6203;P < 0.001)。在显性原发性甲状腺功能减退中,仅在碘限制期间甲状腺功能自发恢复的情况如下:53名RAIU值高于35%的患者中有52名,23名RAIU值在10% - 35%之间的患者中有7名,50名RAIU值低于10%的患者中无一例。因此,高RAIU值可预测恢复情况(P < 0.001;预测率为91.4%)。约80%的可逆性甲状腺功能减退患者发现有甲状腺肿,相比之下,不可逆性甲状腺功能减退患者中只有34%有甲状腺肿。碘限制期间71%的潜在甲状腺功能减退患者甲状腺功能也出现恢复。然而,RAIU测量不能预测潜在甲状腺功能减退患者的预后。我们得出结论,碘诱导的可逆性甲状腺功能减退在我们的患者群体中很常见,并且RAIU测量可能有助于确定显性原发性甲状腺功能减退患者的预后。